Resonance Specialties net profit rises 58% to ₹10.40 crore in FY26
Resonance Specialities Limited reported a 58% rise in net profit to ₹10.40 crore for FY26, with total income increasing 17% to ₹91.89 crore. The board recommended a dividend of ₹1 per share and approved the re-appointment of statutory auditors.
*this image is generated using AI for illustrative purposes only.
Resonance Specialities Limited reported a net profit of ₹10.40 crore for the financial year ended March 31, 2026, a 58% increase from ₹6.57 crore in the previous year. Total income for the period rose 17% to ₹91.89 crore, compared to ₹78.79 crore in FY25, primarily driven by higher sales and export business in key products. The company’s earnings per share (EPS) improved to ₹9.01 from ₹5.69 in the previous year.
Financial Performance
The company’s profit before tax stood at ₹14.07 crore, up from ₹8.88 crore in the previous year. Profit before interest, depreciation, and taxation increased to ₹15.65 crore from ₹11.58 crore. The board has recommended an equity dividend of ₹1 per share (10%) for the financial year, amounting to ₹1.15 crore, which will be paid on or before August 28, 2026, if approved at the Annual General Meeting.
| Particulars | FY26 (₹ in Lacs) | FY25 (₹ in Lacs) |
|---|---|---|
| Total Income | 9,188.93 | 7,878.69 |
| Profit Before Tax | 1,407.35 | 887.82 |
| Net Profit | 1,039.58 | 656.62 |
| Earnings Per Share (₹) | 9.01 | 5.69 |
Operational Highlights
The financial performance improved due to increased sales and export business. The company’s exports, including deemed exports, were recorded at ₹53.55 crore, compared to ₹34.11 crore in the previous year. Resonance Specialities focuses on manufacturing pyridine and pyridine derivatives, picolines, and bulk drugs. The company continues to explore newer markets for its products.
Corporate Governance and Approvals
The board has approved the re-appointment of M/s. Kailash Chand Jain & Co., Chartered Accountants, as statutory auditors for a further period of five years. Additionally, the board has sought shareholder approval to enter into related party transactions with Kaygee Laboratories Private Limited up to a maximum aggregate value of ₹40 crore in any given financial year. The 37th Annual General Meeting is scheduled for August 4, 2026, via video conferencing.
Historical Stock Returns for Resonance Specialties
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +2.66% | +2.00% | +2.08% | +32.22% | +21.93% | -23.40% |
What specific new markets is Resonance Specialities targeting to sustain its export growth momentum?
How will the proposed related party transactions with Kaygee Laboratories impact the company's operational synergy and financial health?
What capital expenditure plans are in place to expand manufacturing capacity for pyridine derivatives and bulk drugs?
20
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
